Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium

Taizo A. Nakano, Bonnie W. Lau, Kathryn E. Dickerson, Marcin Wlodarski, Jessica Pollard, Akiko Shimamura, Inga Hofmann, Ghadir Sasa, Tarek Elghetany, Michaela Cada, Yigal Dror, Hilda Ding, Steven W. Allen, Rabbi Hanna, Kristen Campbell, Timothy S. Olson

Research output: Contribution to journalArticle

Abstract

Background: Myelodysplastic syndromes (MDS) represent a group of clonal hematopoietic stem cell disorders that commonly progress to acute myeloid leukemia (AML). The diagnostics, prognostics, and treatment of adult MDS are established but do not directly translate to children and adolescents. Pediatric MDS is a rare disease, characterized by unique cytogenetics and histology compared with adult MDS, and often arises secondary to germline predisposition or cytotoxic exposures. Our objective was to highlight aspects of diagnosis/management that would benefit from further systematic review toward the development of clinical practice guidelines for pediatric MDS. Procedure: The North American Pediatric Aplastic Anemia Consortium (NAPAAC) is composed of collaborative institutions with a strong interest in pediatric bone marrow failure syndromes and hematologic malignancies. The NAPAAC MDS working group developed a national survey distributed to 35 NAPAAC institutions to assess data on (1) clinical presentation of pediatric MDS, (2) diagnostic evaluation, (3) criteria for diagnosis, (4) supportive care and treatment decisions, and (5) role of hematopoietic stem cell transplantation (HSCT). Results: Twenty-eight of 35 institutions returned the survey. Most centers agreed on a common diagnostic workup, though there was considerable variation regarding the criteria for diagnosis. Although there was consensus on supportive care, treatment strategies, including the role of cytoreduction and HSCT, varied across centers surveyed. Conclusions: There is lack of national consensus on diagnosis and treatment of pediatric MDS. This survey identified key aspects of MDS management that will warrant systematic review toward the goal of developing national clinical practice guidelines for pediatric MDS.

Original languageEnglish (US)
Article numbere28652
JournalPediatric Blood and Cancer
Volume67
Issue number10
DOIs
StatePublished - Oct 1 2020

Keywords

  • aplastic anemia
  • inherited bone marrow failure syndromes
  • myelodysplastic syndromes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium'. Together they form a unique fingerprint.

  • Cite this

    Nakano, T. A., Lau, B. W., Dickerson, K. E., Wlodarski, M., Pollard, J., Shimamura, A., Hofmann, I., Sasa, G., Elghetany, T., Cada, M., Dror, Y., Ding, H., Allen, S. W., Hanna, R., Campbell, K., & Olson, T. S. (2020). Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium. Pediatric Blood and Cancer, 67(10), [e28652]. https://doi.org/10.1002/pbc.28652